tbuckley/cabot-search huggingface dataset:
Akt Activation Regulates Macrophage Survival and Differentiation: Role of M-CSF and Endogenous ROS.
Authors: Yijie Wang, Mandy M. Zeigler, Greg K. Lam, Melissa G. Hunter, Tim D. Eubank, Susheela Tridandapani, Michael C. Ostrowski, Clay B. Marsh
Journal: Blood (2005)
ACTR-25. UP-FRONT BOOST GAMMA KNIFE “LEADING EDGE” RADIOSURGERY (LERS) TO MR FLAIR-DEFINED TUMOR MIGRATION PATHWAYS IN 174 PATIENTS WITH GLIOBLASTOMA MULTIFORME: A 15-YEAR ASSESSMENT OF A NOVEL THERAPY
Authors: Christopher Duma, Peter Chen, Brian Kim, Ralph Mackintosh, Marianne Plunkett, Robert Dillman, Michael Brant-Zawadzki, Burton Eisenberg, Ryan Casserly, Chad Caraway, Ruslana Cannell, Azzurra-Sky Riley, Gustavo Mendez, Marlon Mathews, Daniel Furman, Garrett Smith, David Weiland
Journal: Neuro-Oncology (2016)

Glioblastoma multiforme (GBM) is composed of cells that migrate through the brain along predictable white matter pathways. Targeting white matter pathways adjacentto, and leading away from, the original contrast-enhancing tumor site (“Leading Edge” Radiosurgery,” (LERS)) with single-fraction stereotactic radiosurgery as a boost to standard therapy could limit the spread of glioma cells and improve clinical outcomes. Between December 2000 and May 2016, after an initial diagnosis of GBM, and prior to standard radiation therapy and chemotherapy, 174 patients treated with radiosurgery to the “Leading Edge” (LE) of tumor cell migration were reviewed. The LE was defined as a region outside the contrast-enhancing tumor nidus, defined by FLAIR MRI. The median age was 59 years (range: 22–87). Patients underwent LERS a median of 18 days from original diagnosis. The median target volume of 48.5 cm3(range: 2.5–220.0) of LE tissue was targeted using 8 Gy (range: 6–14) at the 50% isodose line. The median overall survival was 23 months (mean: 43 months) from diagnosis. The 2-, 3, 5-, 7- and 10-year overall survival rates post-LERS were 39%, 26%, 16%, 10% and 4% respectively. Nine percent of patients developed radiation necrosis. Thirty-three patients were hospitalized for management of edema. Surgical resection of a tumor cyst, new tumor bulk, or hydrocephalus occurred in 42 patients. Of the patients with stable disease KPS remained stable in 90% and decreased 1–2 grades in 10%. LERS is a safe and effective upfront adjunctive therapy for patients with newly diagnosed GBM. Limitations of this study include a single center experience and single institution determination of the LE tumor target. A “leading-edge algorithm” will be described to achieve a consistent approach to defining the LE target for general use, as will diffusion tensor imaging. A multi-center trial is warranted.
An Acidic Milieu Created In Myeloma-Osteoclast Interaction Enhances Tumor Growth, but Triggers Anti-Myeloma Activity of Reveromycin A, a Novel Anti-Resorptive Agent
Authors: Keiichiro Watanabe, Masahiro Abe, Qu Cui, Makoto Kawatani, Masahiro Hiasa, Ayako Nakano, Tadashi Jinno, Takeshi Harada, Shiro Fujii, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa, Kyoko Takeuchi, Shuji Ozaki, Eiji Tanaka, Hiroyuki Osada, Toshio Matsumoto
Journal: Blood (2010)
A phase II study of apatinib, a highly selective inhibitor of VEGFR-2, in patients with metastatic solid tumors without standard treatment options
Authors: Y.-K. Kang, M.-H. Ryu, S.R. Park, Y.S. Hong, C.-M. Choi, T.W. Kim, B.-Y. Ryoo, J.E. Kim, S.-W. Kim, J.R. Weis, G. Gilcrease, C. Davidson, R. Kingsford, J. Collett, N. Orgain, S.R. Kim, C.H. Park, A. McGinn, S. Sharma
Journal: Annals of Oncology (2016)
Ranolazine partially blunts ado trastuzumab emtansine related cardiotoxicity
Authors: N. Maurea, C. Coppola, G. Piscopo, G. Riccio, A. Rienzo, C. Maurea, A. Barbieri, C. De Lorenzo, R.V. Iaffaioli
Journal: Annals of Oncology (2016)
Platelet Tissue Factor: Fast and Specific Clotting Activation Pathway Mediated by VWF-GPIba Interaction and Platelet Membrane FVII. Human Platelets Contain All the Components for Assembling the Prothrombinase Complex and Their Procoagulant Function Is Independent of Aggregation/Secretion and GPVI Function.
Authors: Olga Panes, Valeria Matus, Claudia G. Sáaez, Jaime Pereira, Diego Mezzano
Journal: Blood (2009)
The Department of Health and Human Services (DHHS) Sickle Cell Disease (SCD) Initiative: Increasing Access and Improving Care
Authors: Susan B. Shurin, Hani Atrash, Coleen Boyle, R. Lorraine Brown, Janet L. Collins, Sara Copeland, Denise Dougherty, Echezona Ezeanolue, Ann Farrell, Garth N. Graham, Althea M Grant, Dora Hughes, Marsha D. Lillie-Hampton, Peter Lurie, Michael Millman, Bonnie Strickland
Journal: Blood (2011)
A Phase I Clinical Trial of Treatment of B-Cell Malignancies with Autologous Anti-CD19-CAR-Transduced T Cells
Authors: James N. Kochenderfer, Mark E. Dudley, Maryalice Stetler-Stevenson, Wyndham H. Wilson, John E. Janik, Debbie-Ann N. Nathan, Irina Maric, Mark Raffeld, Steven A. Feldman, Richard A. Morgan, Steven A. Rosenberg
Journal: Blood (2010)
Oral Mucositis Measured by the Oral Mucositis Assessment Scale (OMAS), but Not by the World Health Organization (WHO) Scoring System, Correlates with Nutritional Changes after Autologous Peripheral Blood Stem Cell Transplantation.
Authors: Juan J. Toro, Jorge I. Arango, Steven D. Westbrook, Pamela S. Jewell, Lee Shuko, Jose L. Ochoa-Bayona, Cesar O. Freytes
Journal: Blood (2007)
Use of human equilibrative nucleoside transporter 1 to predict survival after adjuvant gemcitabine chemotherapy in resected pancreatic adenocarcinoma.
Authors: S. Morinaga, N. Yamamoto, M. Shiozawa, H. Tamagawa, M. Ueno, Y. Nakamura, Y. Miyagi, S. Ohkawa, K. Yoichi, M. Akaike
Journal: Journal of Clinical Oncology (2011)

224 Background: Gemcitabine is a promising adjuvant treatment for patients with resected pancreatic adenocarcinoma. Human equilibrative nucleoside transporter 1 (hENT1) is the major transporter responsible for 2′, 2′-difluoro-2deoxycytidine (gemcitabine) uptake into cells. The aim of this study was to determine the outcomes according to the expression of hENT1 in tumor cells in patients treated with adjuvant gemcitabine chemotherapy after curative resection. Methods: We studied 27 pancreatic adenocarcinoma patients treated with gemcitabine adjuvant chemotherapy after curative resection and 8 gemcitabine naïve patients between 2006 and 2008. The hENT expressions were assessed using immunohistochemistry. The staining intensity of hENT1 protein was assigned a score from 0 to 3 based on staining with 0: no staining, 1: weakly positive, 2: moderately positive, 3: strongly positive. The percentage of positive tumor cells was scored as follows, 0: no positive tumor cell; 1: &lt; 50% positive cells, 2: 51-80% positive cells, 3: &gt; 81% positive cells. The hENT1 score was obtained by calculating the sum of these two scores. Each patients received adjuvant chemotherapy by either protocols as follows; GEM 1,000 mg/m 2 biweekly × 12 (6 months) or GEM 1,000 mg/m 2 Days 1,8,15; every 4 weeks for 6 months. Results: 11 patients were assigned to low hENT1 expression group (hENT1 score &lt;4) and 16 patients to high hENT1 group (hENT1 score 4,5,6). The median DFS was 7.3 months (95% CI, 3.6-11.1) in the low hENT1 group, and 9.3 months (95% CI, 4.2-14.5) in the high hENT1 group. The median OS was 11.8 months (95% CI, 6.9- 16.6) in the low hENT1 group, and 22.2 months (95% CI, 11.5-32.9). The high hENT1 group had significantly longer DFS (Log-rank, p=0.04) and OS (p=0.02). In the gemcitabine naïve patients after curative resection, neither DFS nor OS correlated with hENT1 expression. Conclusions: In the pancreatic cancer patients treated with adjuvant gemcitabine chemotherapy after curative resection, both DFS and OS correlated with hENT1 expression. The expression of hENT1 may provides prognostic information and predictive for benefit from gemcitabine in these patients. No significant financial relationships to disclose.
Antitumour Activity of Bortezomib-Pegylated Liposomal Doxorubicine Association as Salvage Therapy in Multiple Myeloma Patients.
Authors: Giulia Braccalenti, Pasqualinda Ferrara, Marta Gubbiotti, Paola Cerroni, Lorenzo Falchi, Debora Luzi, Roberta Martiniani, Roberta Pace, Anna Marina Liberati
Journal: Blood (2007)
A phase I dose escalation study of the tolerability of the oral VEGFR and EGFR inhibitor vandetanib in combination with the oral MEK1/2 inhibitor selumetinib in solid tumors
Authors: S. Pacey, F. Blackhall, J. Garcia-Corbacho, A. Lipplaa, A. Fusi, S. Kumar, M. Hategan, J. Derham, G. Laviste, S. Halford, C. Foxton, R. McLeod, S. Wan, D. Talbot
Journal: Annals of Oncology (2016)
Hematologic Outcomes and Erythropoiesis-Stimulating Therapy Costs in Epoetin Alfa (EPO)- and Darbepoetin Alfa (DARB)-Treated Cancer Patients: Results of the Dosing and Outcomes Study of Erythropoiesis-Stimulating Therapies (D.O.S.E. Registry).
Authors: Er Chen, Cyrus Peake, Erminia Buscaino, Jamie Forlenza, Brahim Bookhart, Scott McKenzie
Journal: Blood (2006)
ANGI-05. ANGIOPOIETIN-2 AND VEGFA ASSOCIATE WITH SURVIVAL AND A PRO-ANGIOGENIC PHENOTYPE IN GLIOBLASTOMA
Authors: Siobhan Conroy, Michiel Wagemakers
Journal: Neuro-Oncology (2016)

Glioblastoma (GBM) is a highly aggressive brain tumor characterized by a high rate of vascularization. Although initial responses with anti-angiogenic therapy targeting VEGFA have been described, the therapy has not been able to halt tumor progression durably. Upregulation of alternative pro-angiogenic factors, in particular Angiopoietin-2 (Ang-2), could be an explanation for this lack of improvement. This study therefore addressed the interplay of Ang-2 and VEGFA and their effect on angiogenesis in GBM. The prognostic value of Ang-2 and VEGFA for patient overall survival (OS) was determined in two independent GBM cohorts. Angiogenic signaling levels were determined in GBM tissues and the ability to modulate angiogenesis was assessed through tube formation and chorioallantoic membrane (CAM) assays. Ang-2, VEGFA and the combined high expression of both factors were prognostic for patient overall survival (OS). Although an association between high Ang-2 expression and a pro-angiogenic phenotype was observed, high Ang-2 tumors did not present with higher microvascular density (MVD). Double stimulation with Ang-2 and VEGFA inhibited capillary-like tube formation in vitro,but increased MVD in the CAM assay. Direct stimulation of cells with Ang-2 and VEGFA mainly affected the transcriptional angiogenic expression profile of endothelial cells, but IL-8 was identified as a specific downstream effector of tumor cells following stimulation. Our analyses indicate that Ang-2 and VEGFA are associated with shorter OS of GBM patients. The results also highlight the critical role of Ang-2 signaling in GBM angiogenesis and the synergistic angiogenic effects that Ang-2 exerts with VEGFA.
CD34+ Cells Mobilized with the New CXCR4 Antagonist AMD3100 + G-CSF Show Increased Anti-Apoptotic, Cell Cycle, DNA Repair and Cell Motility-Associated Gene Expression When Compared to G-CSF Mobilization Alone.
Authors: Timon Seeger, Patrick Maier, Li Li, Stephanie Laufs, Volker Eckstein, Gary Bridger, Gary Calandra, Frederik Wenz, Hartmut Goldschmidt, Anthony D. Ho, Stefan Fruehauf
Journal: Blood (2005)
Phase Ia/Ib study of taselisib in Japanese patients with solid tumors or hormone receptor positive breast cancer
Authors: Akihiko Shimomura, Kan Yonemori, Chikako Shimizu, Kenji Nakano, Junichi Tomomatsu, Yoshinori Ito, Shunji Takahashi, Takahiro Minami, Hiroshi Kuriki, Kenji Tamura
Journal: Annals of Oncology (2016)
Role of MicroRNA-486-5p Overexpression In CML CD34+ Cells In Modulating BCR-ABL Mediated Hematopoietic Stem/Progenitor Cell Transformation and Imatinib Sensitivity
Authors: Li-Sheng Wang, Ling Li, Liang Li, Keh-Dong Shiang, Min Li, Su Chu, Ravi Bhatia
Journal: Blood (2011)
Systemic treatment influences on immune accessibility of melanoma: A retrospective histopathological investigation
Authors: L. Krähenbühl, S.M. Goldinger, K. Kerl, W. Kempf, I. Chevolet, L. Brochez, P. Cheng, J. Mangana, M.P. Levesque, R. Dummer
Journal: Annals of Oncology (2016)
Generation of Combined CD8+ and CD4+ T Cell Lines with High Specificity for Adenovirus Hexon Epitopes for Adoptive Immunotherapy after Allogeneic Stem Cell Transplantation.
Authors: Maarten L. Zandvliet, J.H. Frederik Falkenburg, Louise A. Veltrop-Duits, Marco W. Schilham, Roelof Willemze, Henk-Jan Guchelaar, Pauline Meij
Journal: Blood (2008)
Phase Ib/II trial of NC-6004 (nanoparticle cisplatin) plus gemcitabine (G) in pts with advanced solid tumors
Authors: V. Subbiah, A. Combest, J. Griley-Olsen, N. Sharma, E. Andrews, I. Bobe, J. Balkissoon, A. Camp, A. Masada, D. Reitsma, L. Bazhenova
Journal: Annals of Oncology (2016)
Myeloid Cells That Impair Immunotherapy Are Restored in Melanomas with Acquired Resistance to BRAF Inhibitors
Authors: Shannon M. Steinberg, Tamer B. Shabaneh, Peisheng Zhang, Viktor Martyanov, Zhenghui Li, Brian T. Malik, Tamara A. Wood, Andrea Boni, Aleksey Molodtsov, Christina V. Angeles, Tyler J. Curiel, Michael L. Whitfield, Mary Jo Turk
Journal: Cancer Research (2017)

Abstract Acquired resistance to BRAFV600E inhibitors (BRAFi) in melanoma remains a common clinical obstacle, as is the case for any targeted drug therapy that can be developed given the plastic nature of cancers. Although there has been significant focus on the cancer cell-intrinsic properties of BRAFi resistance, the impact of BRAFi resistance on host immunity has not been explored. Here we provide preclinical evidence that resistance to BRAFi in an autochthonous mouse model of melanoma is associated with restoration of myeloid-derived suppressor cells (MDSC) in the tumor microenvironment, initially reduced by BRAFi treatment. In contrast to restoration of MDSCs, levels of T regulatory cells remained reduced in BRAFi-resistant tumors. Accordingly, tumor gene expression signatures specific for myeloid cell chemotaxis and homeostasis reappeared in BRAFi-resistant tumors. Notably, MDSC restoration relied upon MAPK pathway reactivation and downstream production of the myeloid attractant CCL2 in BRAFi-resistant melanoma cells. Strikingly, although combination checkpoint blockade (anti-CTLA-4 + anti-PD-1) was ineffective against BRAFi-resistant melanomas, the addition of MDSC depletion/blockade (anti-Gr-1 + CCR2 antagonist) prevented outgrowth of BRAFi-resistant tumors. Our results illustrate how extrinsic pathways of immunosuppression elaborated by melanoma cells dominate the tumor microenvironment and highlight the need to target extrinsic as well as intrinsic mechanisms of drug resistance. Cancer Res; 77(7); 1599–610. ©2017 AACR.
Reassessment of proliferative activity at disease progression in neuroendocrine neoplasms
Authors: N. Cicchese, F. Panzuto, M. Rinzivillo, E. Merola, G. Capurso, S. Partelli, M. Manzoni, E. Pucci, E. Iannicelli, E. Pilozzi, M. Falconi, Glle De Fave
Journal: Annals of Oncology (2016)
Safety Evaluation of an Fully Human Antagonist Anti-CD40 Antibody, CHIR-12.12, in a Dose Range-Finding Study in Cynomolgus Monkeys.
Authors: Ursula B. Jeffry, Kay Huh, Xia Tong, Julie Klinger, Werner Frings, Antje Fuchs, Nancy Turner, Mohammad Luqman
Journal: Blood (2004)
Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL
Authors: Tabea Erdmann, Pavel Klener, James T. Lynch, Michael Grau, Petra Vočková, Jan Molinsky, Diana Tuskova, Kevin Hudson, Urszula M. Polanska, Michael Grondine, Michele Mayo, Beiying Dai, Matthias Pfeifer, Kristian Erdmann, Daniela Schwammbach, Myroslav Zapukhlyak, Annette M. Staiger, German Ott, Wolfgang E. Berdel, Barry R. Davies, Francisco Cruzalegui, Marek Trneny, Peter Lenz, Simon T. Barry, Georg Lenz
Journal: Blood (2017)
Development of a patient-reported outcome (PRO) instrument to facilitate timing of end-of-life (EOL) discussions in patients with advanced cancers.
Authors: Jose Contreras, Andrew Pecora, Eric V Schultz, Kelly Choi, Augie Smith, Dhakshila Paramanathan, Katie Demarco, Stuart L. Goldberg
Journal: Journal of Clinical Oncology (2015)

74 Background: Honoring the wishes of terminally ill cancer pts is a prime responsibility of oncologists, however EOL discussions are frequently either never performed or delayed past the point of usefulness. Pts who discuss EOL issues with their medical team are more likely to avoid terminal hospitalizations, have improved emotional wellbeing and experience lower health care costs. Facilitators of timely EOL discussions including palliative care consultations would be beneficial. Methods: A 7-item PRO instrument “Living with Cancer” has been developed by COTA (Cancer Outcomes Tracking &amp; Analysis) covering 4 domains: performance status, pain, burden (financial and time), and depression. Each item queried a domain (the pain I experience is: Non-existent, Mild, Moderate, Severe, Unbearable) yielding scores 0 to 4. A unique feature is that each item is multiplied by the pt’s assessment of the importance of the question (multiplier 1-4), yielding a maximum score 112. The pt’s physician (without knowledge of PRO responses) assigned opinions as to status (should continue treatment, beginning to discuss EOL, actively in EOL discussions). Results: 433 pts with advanced malignancies undergoing non-curative therapy completed the PRO instrument between February-March 2014 at the John Theurer Cancer Center. The median scores for pts deemed by their physician appropriate to continue non-curative treatments, contemplating EOL discussions and actively in EOL discussions were 14, 23, and 35 respectively. Results varied by tumor type, with larger differences among cohorts of lung, breast, GI malignancies, and considerable overlap among multiple myeloma pts. A score of &gt; 28 indicated &lt; 25% chance of being in the physician deemed continue therapy group and 40-60% chance of being in the physician determined EOL discussion categories. Conclusions: A 7-item PRO (that includes pt views of importance of each domain) was able to separate advanced malignancy pts into cohorts who their physicians deemed were at differing stages of EOL discussion appropriateness. A prospective study in lung cancer evaluating consultation rates by total score (encouraging discussions if &gt; 28) is ongoing.
RTHP-04. REIRRADIATION FOR DIFFUSE INTRINSIC PONTINE GLIOMA: A SINGLE-INSTITUTION EXPERIENCE
Authors: Sai Duriseti, Cassie Kline-Nunnally, Anuradha Banerjee, Theo Nicolaides, Shannon Raber, Nalin Gupta, Daphne Haas-Kogan, Steve Braunstein, Sabine Mueller
Journal: Neuro-Oncology (2016)

Recurrent diffuse intrinsic pontine glioma (DIPG) is a therapeutic challenge for providers as most patients die within one year after progression. We describe our experience using reirradiation in six recurrent DIPG patients, both with and without concurrent programmed cell death protein 1 (PD-1) inhibition. We completed a retrospective chart review of six pediatric DIPG patients who underwent reirradiation at time of disease recurrence, and report details of their radiation therapy, use of concomitant PD-1 inhibition with nivolumab, and their respective outcomes. A total of six patients (two males, four females) with an average age of nine years at initial diagnosis were included. Median time to reirradiation was eight, and 12 months in patients without, and with PD-1 inhibition, respectively. Three patients received PD-1 inhibition concurrently with radiation. Four patients received 24 Gray (Gy) in 12 fractions, one received 24 Gy in 10 fractions, and one received 30.6 Gy in 17 fractions. Five patients progressed after reirradiation and died of their disease; one remains alive. All patients tolerated reirradiation with no significant side effects, and five of the six patients experienced clinical and radiographic improvement. Median overall survival (OS) from time of reirradiation was five months, and eight months in patients without, and with PD-1 inhibition, respectively. One patient receiving reirradiation with concomitant PD-1 inhibition remains alive without evidence of progression and with significant clinical improvement including near return of independent ambulation and ability to swallow. Our experience demonstrates the feasibility of reirradiation for recurrent DIPG and illustrates its potential efficacy in symptom management and prolongation of life, which may be furthered with the addition of concomitant PD-1 inhibition.
NIMG-07. INFLUENCE OF 2 CONTRASTING TREATMENT PLANNING APPROACHES ON TUMOR TREATING FIELDS (TTFIELDS) INTENSITY IN THE GROSS TUMOR VOLUME (GTV) AND PERITUMORAL BRAIN ZONE (PBZ) IN GLIOBLASTOMA
Authors: Aafia Chaudhry, Ze’ev Bomzon, Hadas Sara Hershkovich, Dario Garcia-Carracedo, Cornelia Wenger, Uri Weinberg, Yoram Palti
Journal: Neuro-Oncology (2016)

TTFields are low-intensity, intermediate frequency, alternating electric fields approved for the management of glioblastoma. TTFields are delivered in orthogonal planes via direct application of transducer arrays (TA) to the scalp. TA placement is planned using MRI data and NovoTAL software, a process optimizing field intensity delivered to the tumor. Glioblastoma frequently recur at the resection cavity margin or proximal PBZ, where infiltrating tumor cells, tumorigenic stromal cells and inflammatory cytokines foster tumor recurrence. Simulation studies demonstrate that field intensities in the GTV and PBZ vary according to TA configuration. We compared the effects conventional treatment planning to the tumor margin (TM) and non-conventional mapping to a wider margin of PBZ, on TTFields intensity delivered to the supratentorial brain. TA layouts were generated for 3 glioblastoma cases using NovoTAL for both standard mapping to the TM using T1 postcontrast sequences, and non-conventional mapping to include a wider margin (20mm) of macroscopically normal PBZ. Electric field simulations were performed for solid, necrotic and resection cavity tumor models. Field intensity was determined in the GTV and PBZ for both approaches. Differences in the median and field intensity frequency distributions for each region were analyzed. Nonconventional mapping significantly shifts TA layout depending on tumor location. TTFields intensity in the GTV and PBZ varies with tumor proprieties and field direction. Standard planning to the TM results in significantly higher field intensities in the GTV and PBZ across tested models. Inclusion of a wider margin of normal PBZ does not increase field intensity in the PBZ. Conventional treatment planning with NovoTAL optimizes field intensity in the GTV and PBZ for glioblastoma patients and may target residual tumor cells in the PBZ, decreasing contiguous recurrence risk. These findings have important implications for the development of clinical practice guidelines for TTFields treatment planning.
Identification and Long-Term Repopulating Potential of Human Cord Blood-Derived CD34−Flt3− Cells with Very Immature Phenotype Using Intra-Bone Marrow Injection.
Authors: Yoshiaki Sonoda, Takafumi Kimura, Rumiko Asada, Jianfeng Wang, Takashi Kimura, Hiroyasu Ishihara, Katsuyasu Kouda, Yutaka Sasaki, Takashi Tsuji, Susumu Ikehara
Journal: Blood (2005)